Francesco Giorgino is Professor of Endocrinology and Chairman of the Department of Precision and Regenerative Medicine and Ionian Area at the University of Bari Aldo Moro, Bari, Italy. He is also Chief of the Division of Endocrinology at the University Hospital Policlinico Consorziale in Bari. Professor Giorgino received his M.D. degree from the University of Bari Aldo Moro and his Ph.D. degree from the University of Naples Federico II, in Italy. After completing clinical training in endocrinology at the University of Catania, Italy, he worked at the Joslin Diabetes Center and Harvard Medical School in Boston, MA, USA, as a postdoctoral research fellow and visiting scientist (1990-1994).
Professor Giorgino has received scientific awards from various institutions, including the Juvenile Diabetes Research Foundation International (JDRF) Fellowship (New York, NY, USA), the Mary K. Iacocca Foundation Fellowship (Boston, MA, USA), the Glaxo-Wellcome Award from the European Association for the Study of Diabetes (EASD), the Aldo Pinchera and Cassano Awards from the Italian Society of Endocrinology, and the Alcmeone Award from the Italian Society of Diabetology. He has been the Italian Delegate in European Commission Cooperation in Science and Technology (COST) actions for diabetes, has been President of the Italian Society of Endocrinology (2019-2021), and is currently Senior Vice-President of the European Association for the Study of Diabetes.
He is or has been a member of the Editorial Boards for PLoS ONE, Journal of Endocrinology, Endocrinology, Journal of Endocrinological Investigation, Adipocyte, Acta Diabetologica, Cardiorenal Medicine, and Diabetes Metabolism Research and Reviews. He has published more than 300 original and review articles and has been an invited speaker at many national and international meetings. His research interests include the mechanisms of insulin resistance and beta-cell dysfunction in type 2 diabetes and the effects of diabetes drugs on pancreatic islets and the cardiovascular system. He has an H-index of 68 and 17,300 citations (Google Scholar).
Duality of interest: Professor Giorgino has received research support / grants from Eli Lilly and Roche Diabetes care and speaker’s honorarium / fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck, Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes care and Sanofi. He has also received board member / advisor panel payments from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck, Sharp & Dohme, Medimmune, Medtronic, Novo Nordisk, Roche Diabetes care, Sanofi, EASD and EFSD together with consultancy payments from Eli Lilly and Novo Nordisk.
Date: Summer 2023